- Home
- PRQR vs OBIO Comparison
PRQR vs OBIO Comparison
Compare PRQR & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | OBIO |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 237.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRQR | OBIO |
|---|---|---|
| Price | $2.11 | $4.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $8.14 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 604.4K | 246.8K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,859,556.00 | $2,818,000.00 |
| Revenue This Year | N/A | $36.43 |
| Revenue Next Year | N/A | $2.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $1.07 | $2.20 |
| 52 Week High | $3.10 | $6.30 |
Technical Indicators
Market Signals| Indicator | PRQR | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 48.42 |
| Support Level | $2.15 | $4.25 |
| Resistance Level | $2.49 | $4.56 |
| Average True Range (ATR) | 0.17 | 0.24 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 31.30 | 16.47 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.